Panel to Review Ciprofloxacin Dispersion for Inhalation NDA
Federal Register notice: FDA has announced a 1/11/2018 Antimicrobial Drugs Advisory Committee meeting. Panel members are expected to discuss an Aradigm Corp. NDA for ciprofloxacin dispersion for inhalation, indicated for treating non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa. To view the notice, click here.